Cardioprotective effects of angiotensin ii type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model

Cardiovascular Therapeutics

Volumn 28, Issue 1, 2010, Pages 30-37

  Dai, Wangde ^a   Hale, Sharon L ^a   Kay, Gregory L ^a   Jyrala, Aarne J ^a   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiotensin II type 1 (AT1) receptor; Cardioprotection; Myocardial infarction; Olmesartan

Indexed keywords

OLMESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; EXPERIMENTAL MODEL; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; LEFT CORONARY ARTERY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMICS; IMIDAZOLES; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 74549172055     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00108.x     Document Type: Article

References (31)

1. Ertl G, Alexander RW, Kloner RA. Interactions between coronary occlusion and the renin-angiotensin system in the dog. Basic Res Cardiol 1983 78 : 518 533.
2. Schulz R, Heusch G. AT1-receptor blockade in experimental myocardial ischemia/reperfusion. Clin Nephrol 2003 60 (Suppl 1 S67 S74.
3. Richard V, Ghaleh B, Berdeaux A, Giudicelli JF. Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 1993 110 : 969 974.
4. Shimizu M, Wang QD, Sjöquist PO, Rydén L. The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther 1999 13 : 347 353.
5. Jugdutt BI, Menon V. AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat. Mol Cell Biochem 2004 262 : 203 214.
6. Sawicki G, Menon V, Jugdutt BI. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail 2004 10 : 442 449.
7. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993 234 : 229 236.
8. Preckel B, Schlack W, Gonzàlez M, Obal D, Barthel H, Thämer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000 95 : 404 412.
9. Kuno A, Miura T, Tsuchida A, Hasegawa T, Miki T, Nishino Y, Shimamoto K. Blockade of angiotensin II type 1 receptors suppressed free radical production and preserved coronary endothelial function in the rabbit heart after myocardial infarction. J Cardiovasc Pharmacol 2002 39 : 49 57.
10. López-Farré A, Sánchez de Miguel L, Montón M, et al. Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant 2001 16 (Suppl 1 45 49.
11. Buczko W, Matys T, Pawlak R, Kucharewicz I, Chabielska E. Studies on the antithrombotic action of AT1 receptor antagonists. Med Sci Monit 2001 7 : 600 605.
12. Schmermund A, Lerman LO, Rumberger JA, Lund PE, Pfeifer EA, Sheedy PF 2nd., Ritman EL. Effects of acute and chronic angiotensin receptor blockade on myocardial vascular blood volume and perfusion in a pig model of coronary microembolization. Am J Hypertens 2000 13 : 827 837.
13. Miura S, Kiya Y, Kanazawa T, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008 22 : 139 146.
14. Yoshida K, Kohzuki M. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Cardiovasc Drug Rev 2004 22 : 285 308.
15. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl 2001 19 : S3 S14.
16. Nussberger J, Koike H. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil. Clin Ther 2004 26 (Suppl A A12 A20.
17. Bhindi R, Witting PK, McMahon AC, Khachigian LM, Lowe HC. Rat models of myocardial infarction. Pathogenetic insights and clinical relevance. Thromb Haemost 2006 96 : 602 610.
18. Bissessor N, White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag 2007 3 : 425 430.
19. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982 65 : 40 48.
20. Przyklenk K, Kloner RA. Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury. Br J Clin Pharmacol 1989 28 (Suppl 2 167S 175S.
21. Linder C, Heusch G. ACE inhibitors for the treatment of myocardial ischemia? Cardiovasc Drugs Ther 1990 4 : 1375 1384.
22. Wang LX, Ideishi M, Yahiro E, Urata H, Arakawa K, Saku K. Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury. Hypertens Res 2001 24 : 179 187.
23. Izumi H, Nakai T, Kano S, Hoshi K, Ichihara K. Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Coron Artery Dis 1996 7 : 775 779.
24. Nakai T, Satoh K, Kosugi T, Hoshi K, Ichihara K. Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium. Eur J Pharmacol 1999 382 : 187 196.
25. Kano S, Satoh K, Kaneta S, Ichihara K. Improvement of stunned myocardium in dogs with olmesartan, an angiotensin II type 1 receptor antagonist, is independent of type 2 receptors. Pharmacology 2008 82 : 22 29.
26. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004 43 : 970 976.
27. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974 54 : 1496 1508.
28. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993 21 : 537 545.
29. Reffelmann T, Kloner RA. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage? Am J Physiol Heart Circ Physiol 2003 284 : H1134 H1141.
30. Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction. Cardiovasc Res 2003 59 : 715 722.
31. Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, Cheng JL, Gao RL. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron Artery Dis 2006 17 : 463 469.